Table 2. Effect of different treatments... | American Society of Hematology

Table 2.

Effect of different treatments on TNF-α/RB6-8C5-induced death

Mouse strain	TNF-α dose, ng/mouse	Pre-TNF-α treatment	Pre-RB6-8C5 treatment	Survival rate	Time to death, min^*
WT	500	Antineutrophil antiserum	None	5/6	16^†
WT	500	Anti-P-selectin	Heparin	2/6	24 ± 2^†
WT	500	Anti-E-selectin	Heparin	0/6	13 ± 1
WT	500	None	Anti-E-selectin + P-selectin + heparin	4/6	13, 17^‡
WT	500	Heparin	None	0/6	15 ± 1
WT	500	rPSGL-Ig	None	0/6	18 ± 2
WT	500	None	rPSGL-Ig + heparin	1/6	19 ± 2
WT	100	None	None	3/6	33 ± 10
WT	20	None	None	6/6	—
C3H/HEJO1a Hsd-Lps^d	500	None	None	0/6	16 ± 0.4

Mouse strain	TNF-α dose, ng/mouse	Pre-TNF-α treatment	Pre-RB6-8C5 treatment	Survival rate	Time to death, min^*
WT	500	Antineutrophil antiserum	None	5/6	16^†
WT	500	Anti-P-selectin	Heparin	2/6	24 ± 2^†
WT	500	Anti-E-selectin	Heparin	0/6	13 ± 1
WT	500	None	Anti-E-selectin + P-selectin + heparin	4/6	13, 17^‡
WT	500	Heparin	None	0/6	15 ± 1
WT	500	rPSGL-Ig	None	0/6	18 ± 2
WT	500	None	rPSGL-Ig + heparin	1/6	19 ± 2
WT	100	None	None	3/6	33 ± 10
WT	20	None	None	6/6	—
C3H/HEJO1a Hsd-Lps^d	500	None	None	0/6	16 ± 0.4

WT indicates wild-type.

Individual times to death are shown for 1 or 2 deaths, otherwise means ± SEMs are shown.

P < .01 for significant difference from 500 ng TNF-α/RB6-8C5 treatment in WT mice.

P < 0.05 for significant difference from 500 ng TNF-α/RB6-8C5 treatment in WT mice.